Encision Reports Second Quarter Fiscal Year 2026 Results

NYSE - LSE

RBGPF	0.12%	82.5	$
SCS	0.12%	16.14	$
CMSC	-0.17%	23.72	$
CMSD	0.12%	24.08	$
BCC	1.86%	82.345	$
JRI	0.57%	13.155	$
NGG	-0.79%	84.6	$
RYCEF	4.19%	16.7	$
RIO	1.18%	92.115	$
BCE	-0.49%	25.735	$
VOD	1.64%	14.895	$
RELX	-0.9%	35.48	$
GSK	1.39%	52.33	$
AZN	-0.7%	189.12	$
BTI	0.31%	60.87	$
BP	-0.56%	37.67	$

Encision Reports Second Quarter Fiscal Year 2026 Results

BOULEVARD 14.11.2025

BOULDER, CO / ACCESS Newswire / November 14, 2025 / Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2026 second quarter that ended September 30, 2025.

Text size:

The Company posted quarterly product net revenue of $1.48 million and service net revenue of $46 thousand, or total net revenue of $1.52 million, resulting in a quarterly net loss of $268 thousand, or $(0.02) per diluted share. These results compare to product net revenue of $1.65 million and service net revenue of $102 thousand, or total net revenue of $1.76 million, resulting in a quarterly net loss of $170 thousand, or $(0.01) per diluted share, in the year-ago quarter. Gross margin on product net revenue was 46% in the fiscal 2026 second quarter and 47% in the fiscal 2025 second quarter.

"Encision continues to fight the attrition of laparoscopic surgical procedure migration to robotics and is focusing our time and resources innovating in segments where robotics are not a factor," says Gregory Trudel the President and CEO of Encision. Our development efforts are culminating in the completion of a new device for the Ear Nose and Throat space that will deliver new levels of patient safety, surgical performance and efficiency, and significant cost savings to hospitals and surgery centers. We expect the product launch in our Q4 and are assembling sales channels and other necessary resources."

Encision Inc. designs and markets a portfolio of high-performance surgical instruments that deliver advances in patient safety, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring (AEM) technology to eliminate dangerous stray energy burns during minimally invasive procedures. For additional information about all our products, please visit www.encision.com.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2025, and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT: Brandon Shepard, Encision Inc., 303-444-2600, [email protected]

Encision Inc.
Condensed Balance Sheets

	September 30, 2025 Unaudited		March 31, 2025 Audited
ASSETS
Current assets:
Cash	$	71,731	$	257,433
Accounts receivable	761,947	786,471
Inventories	1,468,863	1,483,182
Prepaid expenses	144,331	85,679
Total current assets	2,446,872	2,612,765
Equipment:
Furniture, fixtures and equipment, at cost	2,628,661	2,585,446
Accumulated depreciation	(2,378,645	)	(2,340,689	)
Equipment, net	250,016	244,757
Right of use asset	1,116,454	568,395
Patents, net	161,427	171,890
Other assets	81,990	72,892
TOTAL ASSETS	$	4,056,759	$	3,670,699
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	314,815	$	346,900
Line of credit	31,706	395,964
Secured notes	35,202	44,128
Accrued compensation	199,657	180,850
Deferred Revenue	-	17,401
Other accrued liabilities	147,019	160,274
Accrued lease liability	343,172	430,398
Total current liabilities	1,071,571	1,575,915
Long-term liabilities:
Secured notes	162,249	177,470
Accrued lease liability	958,152	266,212
Total liabilities	2,191,972	2,019,597
Commitments and contingencies (Note 4)
Shareholders' equity:
Preferred stock, no par value: 10,000,000 shares authorized; none issued and outstanding	-	-
Common stock and additional paid-in capital, no par value: 100,000,000 shares authorized; 16,879,645 and 11,879,645 issued and outstanding at September 30, 2025, and March 31, 2025, respectively	24,938,998	24,416,347
Accumulated (deficit)	(23,074,211	)	(22,765,245	)
Total shareholders' equity	1,864,787	1,651,102
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$	4,056,759	$	3,670,699

Encision Inc.
Condensed Statements of Operations
(Unaudited)

	Three Months Ended						Six Months Ended
	September 30, 2025		September 30, 2024		September 30, 2025		September 30, 2024
NET REVENUE:
Product	$	1,481,802	$	1,653,820	$	2,974,634	$	3,245,779
Service	46,248	101,568	156,144	140,539
Total revenue	1,528,050	1,755,388	3,130,778	3,386,318

COST OF REVENUE:
Product	805,734	882,886	1,472,545	1,550,520
Service	24,983	44,020	82,441	64,653
Total cost of revenue	830,717	926,906	1,554,986	1,615,173
GROSS PROFIT	697,333	828,482	1,575,792	1,771,145
OPERATING EXPENSES:
Sales and marketing	395,793	458,480	800,394	881,716
General and administrative	358,639	373,405	686,838	725,310
Research and development	201,392	155,515	366,832	294,695
Total operating expenses	955,824	987,400	1,854,064	1,901,721
OPERATING (LOSS)	(258,491	)	(158,918	)	(278,272	)	(130,576	)
Interest expense, net	(11,384	)	(10,598	)	(29,393	)	(16,967	)
Other (expense) income, net	2,042	(746	)	(1,301	)	(679	)
Interest expense and other income (expense), net	(9,342	)	(11,344	)	(30,694	)	(17,646	)
(LOSS) BEFORE PROVISION FOR INCOME TAXES	(267,833	)	(170,262	)	(308,966	)	(148,222	)
Provision for income taxes	-	-	-	-
NET (LOSS)	$	(267,833	)	$	(170,262	)	$	(308,966	)	$	(148,222	)
Net (loss) per share-basic and diluted	$	(0.02	)	$	(0.01	)	$	(0.02	)	$	(0.01	)
Weighted average shares-basic and diluted	14,187,337	11,875,145	13,033,491	11,875,145

Encision Inc.
Condensed Statements of Cash Flows
(Unaudited)

Six Months Ended	September 30, 2025		September 30, 2024
Cash flows (used in) operating activities:
Net (loss)	$	(308,966	)	$	(148,222	)
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation and amortization	48,570	42,525
Stock-based compensation expense related to stock options	22,651	25,011
Provision for potential inventory obsolescence	2,569	83,152
Change in operating assets and liabilities:
Right of use asset, net	56,656	(6,909	)
Accounts receivable	24,524	74,127
Inventories	11,750	154,520
Prepaid expenses and other assets	(55,968	)	15,935
Accounts payable	(49,487	)	(26,678	)
Accrued compensation and other accrued liabilities	5,552	(20,762	)
Net cash (used in) provided by operating activities	(242,149	)	192,699
Cash flows (used in) investing activities:
Acquisition of property and equipment	(43,215	)	(42,559	)
Patent and Trademark costs	(11,933	)	(17,359	)
Net cash (used in) investing activities	(55,148	)	(59,918	)
Cash flows from financing activities:
(Repayments) Borrowing from line of credit	(364,258	)	(77,834	)
(Payments) from options exercised	-	(1,449	)
Proceeds from issuance of common stock	500,000	-
(Paydown) Draw on Secured notes	(24,147	)	134,007
Net cash provided by financing activities	111,595	54,724

Net (decrease) increase in cash	(185,702	)	187,505
Cash, beginning of fiscal year	257,433	42,509
Cash, end of six months	$	71,731	$	230,014

Supplemental disclosures of cash flow information:
Cash paid during the year for interest	$	29,393	$	16,967

SOURCE: Encision, Inc.

View the original press release on ACCESS Newswire

O.Gutierrez--AT

Arizona Tribune - Encision Reports Second Quarter Fiscal Year 2026 Results

Encision Reports Second Quarter Fiscal Year 2026 Results

Featured

Twenty-one friends from Belgian village win €123mn jackpot

UK ex-ambassador quits Labour over new reports of Epstein links

Rural Health Transformation Reality Check: What Rural Hospital Decision-Makers Will Fund in 2026 and What They Won't

NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres